<SEC-DOCUMENT>0001193125-22-273339.txt : 20221031
<SEC-HEADER>0001193125-22-273339.hdr.sgml : 20221031
<ACCEPTANCE-DATETIME>20221031090534
ACCESSION NUMBER:		0001193125-22-273339
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20221031
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221031
DATE AS OF CHANGE:		20221031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gemini Therapeutics, Inc. /DE
		CENTRAL INDEX KEY:			0001816736
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851613057
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39438
		FILM NUMBER:		221343930

	BUSINESS ADDRESS:	
		STREET 1:		300 ONE KENDALL SQUARE, 3RD FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		(617) 401-4400

	MAIL ADDRESS:	
		STREET 1:		300 ONE KENDALL SQUARE, 3RD FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FS Development Corp.
		DATE OF NAME CHANGE:	20200702
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d363220d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:gmtx="http://geminitherapeutics.com/20221031" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2022-10-31_to_2022-10-31">Gemini Therapeutics, Inc. /DE</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2022-10-31_to_2022-10-31">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2022-10-31_to_2022-10-31">0001816736</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="gmtx-20221031.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2022-10-31_to_2022-10-31"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001816736</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-31</xbrli:startDate> <xbrli:endDate>2022-10-31</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2022-10-31_to_2022-10-31">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2022-10-31_to_2022-10-31" format="ixt:datemonthdayyearen">October&#160;31, 2022</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">GEMINI THERAPEUTICS, INC.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2022-10-31_to_2022-10-31" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2022-10-31_to_2022-10-31">001-39438</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2022-10-31_to_2022-10-31">85-1612845</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2022-10-31_to_2022-10-31">297 Boston Post Road #248</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2022-10-31_to_2022-10-31">Wayland</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2022-10-31_to_2022-10-31">MA</ix:nonNumeric></span><sup style="font-size:75%; text-align: center;margin:auto; vertical-align:top">1</sup><span style="font-weight:bold"></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2022-10-31_to_2022-10-31">01778</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2022-10-31_to_2022-10-31">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2022-10-31_to_2022-10-31">401-4400</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-style:italic">see</span> General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2022-10-31_to_2022-10-31" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2022-10-31_to_2022-10-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2022-10-31_to_2022-10-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)&#160;under</span> the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2022-10-31_to_2022-10-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)&#160;under</span> the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2022-10-31_to_2022-10-31">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2022-10-31_to_2022-10-31">GMTX</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2022-10-31_to_2022-10-31" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2022-10-31_to_2022-10-31" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2022-10-31_to_2022-10-31" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top">1</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The Company does not currently maintain a physical headquarters but maintains a mailing address at 297 Boston Post Road #248, Wayland, MA&#160;01778.</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, on August&#160;9, 2022, Gemini Therapeutics, Inc., a Delaware corporation (&#8220;Gemini&#8221; or the &#8220;Company&#8221;), Gemstone Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gemini (&#8220;Merger Sub&#8221;), and Disc Medicine, Inc., a Delaware corporation (&#8220;Disc&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Disc, with Disc continuing as a wholly owned subsidiary of Gemini and the surviving corporation of the merger (the &#8220;Merger&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;31, 2022, Disc issued a press release announcing the initiation of AURORA (the &#8220;Study&#8221;), a Phase 2 clinical study of Bitopertin in patients with Erythropoietic Protoporphyria. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furnished as Exhibit 99.2 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein by reference are social media posts posted by Disc on LinkedIn and Twitter on October&#160;31, 2022 regarding the announcement of the Study initiation. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Current Report on Form <span style="white-space:nowrap">8-K</span> and the exhibits attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements (including within the meaning of Section&#160;21E of the Exchange Act and Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)) concerning Gemini, Disc, the proposed transaction and other matters. These forward-looking statements include express or implied statements relating to Gemini&#8217;s management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Gemini, Disc or the proposed transaction will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Gemini&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the closing of the transaction are not satisfied, including the failure to obtain stockholder approval for the transaction; the risk that the concurrent financing is not completed in a timely manner or at all; uncertainties as to the timing of the consummation of the transaction and the ability of each of Gemini and Disc to consummate the transaction, including the concurrent financing; risks related to Gemini&#8217;s continued listing on the Nasdaq Stock Market until closing of the proposed transaction; risks related to Gemini&#8217;s and Disc&#8217;s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, as well as uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon closing </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and other events and unanticipated spending and costs that could reduce the combined company&#8217;s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Gemini&#8217;s or Disc&#8217;s business relationships, operating results and business generally; costs related to the merger; the outcome of any legal proceedings that may be instituted against Gemini, Disc or any of their respective directors or officers related to the merger agreement or the transactions contemplated thereby; the ability of Gemini or Disc to protect their respective intellectual property rights; competitive responses to the transaction; unexpected costs, charges or expenses resulting from the transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction; legislative, regulatory, political and economic developments; and those factors described under the heading &#8220;Risk Factors&#8221; in the Gemini&#8217;s most recent Annual Report on Form <span style="white-space:nowrap">10-K</span> filed with the SEC and the registration statement on Form <span style="white-space:nowrap">S-4</span> initially filed with the SEC on September&#160;2, 2022, as well as discussions of potential risks, uncertainties, and other important factors included in later filings, including any Quarterly Reports on Form <span style="white-space:nowrap">10-Q</span> and Current Reports on Form <span style="white-space:nowrap">8-K.</span> Should one or more of these risks or uncertainties materialize, or should any of Gemini&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the ongoing <span style="white-space:nowrap">COVID-19</span> pandemic and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Gemini&#8217;s forward-looking statements only speak as of the date they are made, and Gemini does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Offer or Solicitation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Important Additional Information Will be Filed with the SEC </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed transaction between Gemini and Disc, Gemini intends to file relevant materials with the SEC, including a registration statement on Form <span style="white-space:nowrap">S-4</span> that contains a proxy statement/prospectus of Gemini and information statement of Disc, which was initially filed with the SEC on September&#160;2, 2022. GEMINI URGES INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GEMINI, DISC, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of the proxy statement/prospectus/information statement and other documents filed by Gemini with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and shareholders should note that Gemini communicates with investors and the public using its website (www.geminitherapeutics.com) and the investor relations website (https://investors.geminitherapeutics.com/) where anyone will be able to obtain free copies of the </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proxy statement/prospectus/information statement and other documents filed by Gemini with the SEC and stockholders are urged to read the proxy statement/prospectus/information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the proposed transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Participants in the Solicitation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gemini, Disc and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about Gemini&#8217;s directors and executive officers is included in Gemini&#8217;s most recent Annual Report on Form <span style="white-space:nowrap">10-K,</span> including any information incorporated therein by reference as filed with the SEC, and the registration statement on Form <span style="white-space:nowrap">S-4</span> initially filed with the SEC on September&#160;2, 2022, and any amendments thereto as filed with the SEC. These documents can be obtained free of charge from the sources indicated above. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(d) <span style="font-style:italic">Exhibits</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d363220dex991.htm">Press release issued by Disc Medicine, Inc. on October&#160;31, 2022</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d363220dex992.htm">Social media posts, posted by Disc Medicine, Inc. on October&#160;31, 2022</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:44%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="3" style="vertical-align:bottom;white-space:nowrap">GEMINI THERAPEUTICS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: October&#160;31, 2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Georges Gemayel</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Dr.&#160;Georges Gemayel</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Interim President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d363220dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g363220snap0044.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic
Protoporphyria (EPP) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>AURORA study designed to evaluate bitopertin as a potential disease-modifying treatment for adults with EPP in
the United States</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>AURORA study designed to assess changes in protoporphyrin IX levels, safety, tolerability, photosensitivity
and other measures in a double-blind, placebo-controlled setting; <FONT STYLE="white-space:nowrap">top-line</FONT> data expected in 2023</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WATERTOWN, Mass. (October 31, 2022) &#150; Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and
commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today the initiation of AURORA, a Phase 2 clinical study of bitopertin in adults with EPP. Bitopertin is an oral, selective inhibitor of
glycine transporter 1 (GlyT1) designed to modulate heme biosynthesis, and has been shown in preclinical studies to reduce accumulation of protoporphyrin IX (PPIX), the toxic metabolite that causes disease pathology in EPP patients. Bitopertin is
also currently being studied in BEACON, an open-label Phase 2 clinical study in patients with EPP and <FONT STYLE="white-space:nowrap">X-linked</FONT> protoporphyria (XLP), which was announced in August 2022 and is being conducted in Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to initiate AURORA, the first <FONT STYLE="white-space:nowrap">US-based</FONT> study of bitopertin in patients with EPP. We are
conducting the AURORA study to enable us to evaluate the effects of bitopertin on PPIX levels, photosensitivity, pain and other key measures in a rigorous, blinded trial,&#148; said John Quisel, JD, PhD, Chief Executive Officer at Disc Medicine.
&#147;We have designed AURORA and BEACON to provide us with a robust assessment of bitopertin&#146;s potential as a disease-modifying therapy for EPP.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AURORA Phase 2 study is a randomized, double-blind, placebo-controlled, parallel dosing clinical trial designed to evaluate the safety, tolerability, and
efficacy of bitopertin in adults with EPP. It is expected to enroll approximately 75 patients at sites throughout the United States. Patients will receive orally-administered bitopertin for 120 days at doses of either 20 mg once-daily or 60 mg
once-daily. Upon completion of the <FONT STYLE="white-space:nowrap">120-day</FONT> treatment period, patients may roll over to the open-label extension portion of the trial. The study is designed to measure changes in levels of metal-free PPIX, as
well as measures of photosensitivity, daylight tolerance, pain, safety, and tolerability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;There is a significant unmet need for disease-modifying
therapies for EPP that address the underlying pathophysiology of the condition. Patients with EPP experience debilitating painful reactions, as well as potentially severe hepatobiliary effects, and the measures they must take to avoid the sun can
have a strong, negative impact on their quality of life,&#148; said Cynthia Levy, MD, FAASLD, AGAF, University of Miami Miller School of Medicine. &#147;We are very excited about the potential for bitopertin to address the underlying protoporphyrin
accumulation that causes EPP symptoms and hepatopathy, and we look forward to the results.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Bitopertin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bitopertin is a clinical-stage, orally administered inhibitor of GlyT1 that is designed to modulate heme biosynthesis. GlyT1 is a membrane transporter
expressed on developing red blood cells and is required to supply sufficient glycine for heme biosynthesis and support erythropoiesis. The safety profile and effects of bitopertin on heme biosynthesis were previously established in a comprehensive
clinical program comprising over 4,000 individuals across multiple clinical studies. Disc Medicine is planning to develop bitopertin as a potential treatment for a range of hematologic diseases beginning with EPP and XLP. In preclinical models of
EPP and XLP, bitopertin was shown to significantly decrease PPIX, a toxic intermediate of heme biosynthesis which is the underlying cause of the disease. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bitopertin is an experimental agent and is not approved for use as a therapy in any jurisdiction worldwide.
Disc obtained global rights to bitopertin under a license agreement from Roche in May 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Erythropoietic Protoporphyria (EPP) and <FONT
STYLE="white-space:nowrap">X-linked</FONT> Protoporphyria (XLP) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EPP and XLP are rare, debilitating and potentially life-threatening diseases caused by
mutations that affect heme biosynthesis, resulting in the accumulation of a toxic, photoactive intermediate called protoporphyrin IX (PPIX). This causes severe reactions when patients are exposed to sunlight, characterized by excruciating pain,
edema, burning sensations and potential blistering and disfigurement. PPIX also accumulates in the hepatobiliary system and can result in complications including gallstones, cholestasis, and liver damage in
<FONT STYLE="white-space:nowrap">20-30%</FONT> of patients and in extreme cases liver failure. Current standard of care involves extreme measures to avoid sunlight, including restricting outdoor activities to nighttime, use of protective clothing
and opaque shields, and pain management. This has a significant impact on the psychosocial development, quality of life, and daily activities of patients, particularly in young children and families. There is currently no cure for EPP and only one <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> therapy, a surgically implanted synthetic hormone designed to stimulate melanin production called Scenesse<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (afamelanotide). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Disc Medicine </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disc Medicine is a clinical-stage
biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a portfolio of innovative, potentially
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutic candidates that affect fundamental pathways of red blood cell biology. We are committed to developing treatments that empower and bring hope
to the many patients who suffer from hematologic diseases. In August 2022, Disc announced it entered into a definitive merger agreement with Gemini Therapeutics, Inc. (NASDAQ:GMTX). For more information, please visit www.discmedicine.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disc Medicine Cautionary Statement Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this press release may constitute &#147;forward-looking statements&#148; for purposes of the federal securities laws concerning
Disc&#146;s expectations with respect to its AURORA clinical study and other matters, including the proposed transaction between Disc and Gemini Therapeutics, Inc. (Gemini) announced in August 2022. These forward-looking statements include express
or implied statements relating to Disc&#146;s management team&#146;s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future
events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar
expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments
and their potential effects. There can be no assurance that future developments affecting Disc, Gemini or the proposed transaction will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties
(some of which are beyond Disc&#146;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include,
but are not limited to, the risk that the conditions to the closing of the transaction are not satisfied, including the failure to obtain stockholder approval for the transaction; the risk that the concurrent financing is not completed in a timely
manner or at all; uncertainties as to the timing of the consummation of the transaction and the ability of each of Gemini and Disc to consummate the transaction, including the concurrent financing; risks related to Gemini&#146;s continued listing on
the Nasdaq Stock Market until closing of the proposed transaction; risks related to Gemini&#146;s and Disc&#146;s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, as well as
uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company&#146;s cash
resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Gemini&#146;s or Disc&#146;s business
relationships, operating </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results and business generally; costs related to the merger; the outcome of any legal proceedings that may be instituted against Gemini, Disc or any of their respective directors or officers
related to the merger agreement or the transactions contemplated thereby; the ability of Gemini or Disc to protect their respective intellectual property rights; competitive responses to the transaction; unexpected costs, charges or expenses
resulting from the transaction; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction; and legislative, regulatory, political and economic developments. The foregoing list
of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the &#147;Risk Factors&#148; section of the proxy statement/prospectus included in the registration statement on
Form <FONT STYLE="white-space:nowrap">S-4</FONT> which was initially filed with the SEC in September 2022 in connection with the transaction and other documents filed by Gemini from time to time with the SEC. Should one or more of these risks or
uncertainties materialize, or should any of Disc&#146;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be
amplified by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Disc&#146;s
forward-looking statements only speak as of the date they are made, and Gemini and Disc do not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as
may be required under applicable securities laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to
purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of
applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the
public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation,
facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information Will be Filed with the SEC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed transaction between Gemini and Disc, Gemini intends to file relevant materials with the SEC, including a registration statement
on Form <FONT STYLE="white-space:nowrap">S-4</FONT> that contains a proxy statement/prospectus of Gemini and information statement of Disc, which was initially filed on September&nbsp;2, 2022. DISC URGES INVESTORS AND STOCKHOLDERS TO READ THESE
MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT GEMINI, DISC, THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and shareholders will be able to obtain free copies of
the proxy statement/prospectus/information statement and other documents filed by Gemini with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. In addition, investors and shareholders should note that
Gemini communicates with investors and the public using its website (www.geminitherapeutics.com), the investor relations website (https://investors.geminitherapeutics.com/) where anyone will be able to obtain free copies of the proxy
statement/prospectus/information statement and other documents filed by Gemini with the SEC and stockholders are urged to read the proxy statement/prospectus/information statement and the other relevant materials when they become available before
making any voting or investment decision with respect to the proposed transaction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gemini and its directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction.
Information about Gemini&#146;s directors and executive officers is included in Gemini&#146;s most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> including any information incorporated therein by reference, as filed with
the SEC, and the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> initially filed with the SEC on September&nbsp;2, 2022, and any amendments thereto as filed with the SEC. These documents can be obtained free of charge from
the sources indicated above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disc
Medicine, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peg Rusconi (Media) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Verge Scientific
Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">prusconi@vergescientific.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christina
Tartaglia (Investor) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stern Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">christina.tartaglia@sternir.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gemini Therapeutics, Inc.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian Piekos </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gemini Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(617) <FONT STYLE="white-space:nowrap">401-4400</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR@geminitherapeutics.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d363220dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g363220snap0044.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disc Medicine | Blood Cancer Awareness Month / AURORA Social Media </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>LinkedIn</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Twitter&nbsp;(max&nbsp;280&nbsp;characters)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Image</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">31,&nbsp;2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disc is delighted to announce the initiation of AURORA, our <FONT STYLE="white-space:nowrap">US-based</FONT> Phase 2 Study of bitopertin in
Erythropoietic<BR>protoporphyria (#EPP) patients. Learn more about bitopertin and the AURORA trial here: [link to press release]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Bitopertin is an experimental agent and is not approved for use as a therapy in any jurisdiction worldwide.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disc is delighted to announce the initiation of AURORA, our <FONT STYLE="white-space:nowrap">US-based</FONT> Phase 2 Study of bitopertin in
#EPP patients. Learn more: [link to press release]</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bitopertin is an experimental
agent and is not approved for use as a therapy in any jurisdiction worldwide.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(247/280 char)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g363220snap0045.jpg" ALT="LOGO">
</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>gmtx-20221031.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/31/2022 1:31:07 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2021-01-31"
  xmlns:gmtx="http://geminitherapeutics.com/20221031"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://geminitherapeutics.com/20221031"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" namespace="http://xbrl.sec.gov/dei/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gmtx-20221031_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="gmtx-20221031_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>gmtx-20221031_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/31/2022 1:31:08 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>gmtx-20221031_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20220115.12 -->
<!-- Creation date: 10/31/2022 1:31:08 PM Eastern Time -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="gmtx-20221031.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g363220snap0044.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g363220snap0044.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M &=J>H-IMJUQ'IVHZHZ\)9Z7#%-=.0,X7[1/!$GUDE0>]3.7(KJ,I6Z12O\
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M2,IM(@OVL(FU(%4NCF5+ 9+A<3A\)RTY5'!4_:.Z=YWDYN+<FW&[T6_D1F/
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MI$?[+'@VR73[46VN>'_$<^KQ&%"NI2W^IZQ;W;WH*_Z07MEC@._=^ZB2/[J
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M.^(.-L7#$9QB(QP]!R^KX.BG##8=/1N,&Y.51I)2JU)2J/:ZC:*]JKO/C0H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
A H * "@ H * "@ H * "@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g363220snap0045.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g363220snap0045.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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ML?TZ4!M\A<?AC]/PI;!M\A.GX?ICMBG^@;>0=/;V[ 4?H&WR#M]/THV^0OT
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M_K4?A86WR% Q^']*![![>A]NU&WE86WE83IC'^<4;?(>WR _R_3]*-O*P?H
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MQQH**.LAU#PC->7,4??,]A#QR1Q1_:<Z/^^9?B<-;>48*O3_ / J+E)+_%!
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M)[J+U/TRAQ1E'%U&EEG'SE1S&G"-+!\3T:?M,9145:G2SBC&SS/"15HJNO\
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MM1:527MG3CI^G3IVKUMOD?G(8Q[8_#ITHO;Y!M\@';CI_3K^5&WE8/P%Q_\
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MHR]>T"SUZT\F<"*XC!-K=*H,D#GL?[\+'&Y#]1@@&LL1AX5X<K]V4?AEU7_
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M+^M ^'RL3I"!C=S_ +(XZ>IKOI8-1LZCYFOLK;Y]_P O4AR[:6)P,# & /P
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M D$:JHVJ@VJH]N@Z?F:Z)SA1A=Z*.R\^B/";E4FY2=Y2U?\ 7D5F8L<G\!V
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MQC_:"D-Z.K>M&#K^VI)2_B4])?H_GU\Q\0Y7_9N-;I+_ &3%7G1:VC_-3O\
MW7K'^XXG8UUGSY@^)[^;3-!U&]M\":**-(B>-CW$\5L) /[R>;N ]5%88FI*
MC0J3CO%)+RNU&_RO<]7),)3QN:8/"U?X4Y2<EW5.$JG+Y*7)RM]$V97@W0_[
M(TQ99U(O[_;<7+-]]$(+0P$GG*JQ9O\ :<YZ5G@J'L*2;7[RIK+R[+_/S.SB
M/,_[0QSITG_LF$O3II?"VM)S27=JT?[J7<Z.\N!:0%@?G(VQ#K\Q[X] .?\
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M-OD&WR./O9C<W+%<E5(CB7V4X&/=B2?QKDF^:7IHD?0X6E["A%/W7\4GV?\
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MZ>?2NC#XJMA7>E*RZQ>L7\OU5F2XI^5C1BG608^ZPZJ?;^Z:^APF.I8E<O\
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M*^G5$']/TQ7#L5^A)&YB8'MT8>H'TK?#5Y8>HI+6.TEW7^:W0G&ZMVV-)2"
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M[HS^GX?TKRM/N-=OD'3_ #Z4M@_0.GX4+\@V^0=/;'X8HV#;Y#D&64=,'Z8
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M#V^0=/;'Z8I[>0;?(4<?A^F*-@V^0=,=L?AC'M2_0-@Z?Y_SQ1M\@_03I^%
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M67('.,D8QTZ&IJ4J=6/)4BI13O9]UML";CMI89]F@'_+-1CZCI^-8?4,(O\
MEQ%6]?\ ,?/)=0^S0#_EFO'U_P :/J&$7_+B*MZ_YASR[A]F@'_+-1CZC&/Q
MH^H83_GQ'\?\PYY+K:PQK*U8Y:%21QR6[?\  JQGE.75&G/"QDXJRUEM\I#5
M2:^U83[#:?\ /%?S;_XJH_L7*U_S!P5O.7_R0>TFOM!]AM/^>*_FW;_@5']B
MY6O^8."MYR_^2#VDU]H/L-I_SQ7CW;M_P*C^Q<K7_,'!6\Y?_)![2:^T'V&T
M_P">*\>[=O\ @5']BY6O^8.&GG+_ .2#VD_Y@^PV@_Y8KQ[M_P#%4?V+E:_Y
M@X:><O\ Y(/:37V@^PVG_/%?S;M_P*C^Q<K7_,'#[Y?_ "0>TFOM;!]AM!_R
MQ7\V_P#BJ/[%RM?\P<%;SE_\D'M)K[0?8;0?\L5'XL.G_ J/[%RO_H#AIYR_
M^2#VDU]K8/L%I_SQ7CW?_P"*H_L7*U_S!PT\Y?\ R0>TG_-L'V&T_P">*_F_
M_P 51_8N5_\ 0'#3SE_\D'M)K[6P?8+3_GBO'NW&/^!4?V+E:_Y@X??+_P"2
M#VD_YM@^PV@_Y8KQ[M_\51_8N5_] <-/.7_R0>TFOM;!]AM!_P L%&/=ATZ?
MQ4?V+E:_Y@X*WG+_ .2#VD_YM@^PV@_Y8J,>[#I_P*C^Q<K_ .@.&GG+_P"2
M#VDU]K8/L-H/^6*\>[]NG\5']BY7_P! </OE_P#)![2:^UL'V&T'_+%1CW88
MQQ_>H_L7*U_S!PT\Y?\ R0>TFOM6L'V&T'_+%?S;M_P*C^Q<K_Z X:><O_D@
M]I-?:#[!:?\ /%>/=_\ XJC^Q<K7_,'#3SE_\D'M)_S;!]AM!_RQ7\VXQ_P*
MC^Q<K_Z X:><O_D@]I-?:#[!:#_EBOYO_P#%4?V+E?\ T!PT\Y?_ "0>TFOM
M;#UM+=!A8E4#MEN/UK:&6X&G%1AAXQC'97E^K#GEWV%^S0#_ )9J/S']:OZA
M@_\ GQ'3U_S%SR[[!]F@'_+,#'U']:/J&#7_ "XCIZ_YASR[[!]F@'_+,<?7
MMT[T?4,(O^7$5;U_S#GDNMB7:/3I]>U=>WR)&M%&WWE!(XYSP!^-8U,/1JM.
MI34G%63UV^0U)QV=AOV>$?\ +,<?7_&H^IX9?\N5IYO_ #'S2778<L4:?=4+
MTZ9[=.]:4Z-*C=4H<G-O:_3;J)M]]AVT#M^I[>U:_H+;RL&Q?3I]:/(-O*PW
MR8Q_"./<\8_&L?J]%?\ +M*WK_F5S-=;6'!%4  8"]!D\8_&M8Q4$HQ7*H[(
MD-H].GN>U/\ 0-OD&T#MT^O%&WD&WD-,4?\ ='Z_XUE*A2DVW!-O?<:;76UA
M/)B'\ X^O;\:7U>BO^7:T]?\Q\S[[!Y,0_@ _,?UH^KT?^?:T]?\Q<S778/)
MC'\ X^O;\:/J]%?\NTK>O^8^9KK:P>3%_<'Z]OQH^KT5_P NTK>O^8<S778E
MK8D* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
4H * "@ H * "@ H * "@ H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139656887157424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gemini Therapeutics, Inc. /DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001816736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1612845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">297 Boston Post Road #248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wayland<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-4400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GMTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d363220d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gmtx-20221031.xsd" xlink:type="simple"/>
    <context id="duration_2022-10-31_to_2022-10-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001816736</identifier>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2022-10-31_to_2022-10-31"
      id="Hidden_dei_EntityRegistrantName">Gemini Therapeutics, Inc. /DE</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2022-10-31_to_2022-10-31">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2022-10-31_to_2022-10-31"
      id="Hidden_dei_EntityCentralIndexKey">0001816736</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2022-10-31_to_2022-10-31">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2022-10-31_to_2022-10-31">2022-10-31</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2022-10-31_to_2022-10-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2022-10-31_to_2022-10-31">001-39438</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2022-10-31_to_2022-10-31">85-1612845</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2022-10-31_to_2022-10-31">297 Boston Post Road #248</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2022-10-31_to_2022-10-31">Wayland</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2022-10-31_to_2022-10-31">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2022-10-31_to_2022-10-31">01778</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2022-10-31_to_2022-10-31">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2022-10-31_to_2022-10-31">401-4400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2022-10-31_to_2022-10-31">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2022-10-31_to_2022-10-31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2022-10-31_to_2022-10-31">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2022-10-31_to_2022-10-31">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2022-10-31_to_2022-10-31">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2022-10-31_to_2022-10-31">GMTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2022-10-31_to_2022-10-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2022-10-31_to_2022-10-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2022-10-31_to_2022-10-31">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ L$A?59>*NQS
M$P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B
M#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z1
M0J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ
M0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?V
MD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "P2%]5
M'#AEZC\!   \ @  #P   'AL+W=O<FMB;V]K+GAM;(U1RV["0 S\E=5^0!-0
MBU1$N)0^D*H6E8K[DG6(Q3XBKP,M7U\G452D7GKR>FR-9V87YTC'?8Q']>5=
M2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ O<NF>3[+O,&@EXN1:T/9
M=1,92L88!.R '<(Y_<Z[5ITPX1X=\G>A^[<#K3P&]'@!6^A<JU3'\TLDO,3
MQFU+BLX5>C(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=
MR_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D
M&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&
ML&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @
ML$A?520>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ L$A?50=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "P2%]5URQ5
M&^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " "P2%]5F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +!(7U53>I7H< 0  #01
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " "P2%]5GZ ;\+$"  #B#   #0              @ &S#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +!(7U67BKL<P    !,"   +
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4!08     "0 ) #X"   3%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d363220d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d363220d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d363220d8k.htm">d363220d8k.htm</File>
    <File>d363220dex991.htm</File>
    <File>d363220dex992.htm</File>
    <File>gmtx-20221031.xsd</File>
    <File>gmtx-20221031_lab.xml</File>
    <File>gmtx-20221031_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d363220d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d363220d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gmtx-20221031_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gmtx-20221031_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gmtx-20221031.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "gmtx",
   "nsuri": "http://geminitherapeutics.com/20221031",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d363220d8k.htm",
      "contextRef": "duration_2022-10-31_to_2022-10-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d363220d8k.htm",
      "contextRef": "duration_2022-10-31_to_2022-10-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://geminitherapeutics.com//20221031/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001193125-22-273339-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-273339-xbrl.zip
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MH2(F;J$ED_18N'O-U2&&50[7Y$-UM&NUJ99@.D9]OP-Q;=.%#B;P^MCE\SE
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M1$;E *.CUJ+=SB IVN= 319@$(%=IA>*8CT<G"+R)>0!^68"% G\S=,U[V*
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M>1.&:0I:B*N7;X\],0(GUI:]KG39:]UHZ*0Z#-TYW('@V3_]'U!+ P04
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M$#T_.NX^?WYTY*/1UU[6</SK[ASB >(*HQA=?,1%_D6,_PM02P,$%     @
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M7((OVK8@W=D**;JSU;,(D\28R_]'KDFQ0M]XA!6>+;__8;OD*CC*R[TN,$_
MYD?,FWF>4Y?\#5!+ 0(4 Q0    ( +!(7U4D(28A1AP  $69   .
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M,#,Q7VQA8BYX;6Q02P$"% ,4    " "P2%]5%;S,TM<$  !*+   %0
M        @ 'S0P  9VUT>"TR,#(R,3 S,5]P<F4N>&UL4$L%!@     &  8
*?P$  /U(      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
